Loading…
Loading…
just wondering if you could provide any color on the order growth or book-to-bill in the quarter
There is a 20% pricing rebate for those manufacturing locally. This is beyond the VBP and the DRG headwinds
Can you talk to us about the updated number there? And just given the inter-quarter changes with US-China trade
how broad is the exposure to gene therapies? And I totally recognize that, you know, innovation doesn't come without risk
could you elaborate what you're hearing from your larger biopharma large cap customers versus the early emerging biotechs